CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced positive topline results from its Phase 2 HELIOS trial of AMX0035 in adults with Wolfram syndrome, a rare and progressive disease. The trial demonstrated an improvement in pancreatic function, a key measure of disease progression, over a 24-week treatment period.
The HELIOS trial evaluated 12 adults with Wolfram syndrome, a condition that affects approximately 3,000 people in the U.S. and is characterized by diabetes, optic nerve atrophy, and neurodegeneration. The primary efficacy endpoint, C-peptide response, showed an increase from baseline after 24 weeks, indicating an improvement in pancreatic function, contrary to the typical expectation of decline due to the disease's progression.
Secondary endpoints, including glycemic control and vision, also showed improvements or stabilization. Both patient- and physician-reported global impressions of change indicated disease stability or improvement in all participants.
Long-term data from participants who completed Week 36 and Week 48 assessments revealed sustained improvements over time. The trial's safety profile was consistent with previous data, with AMX0035 being well-tolerated and most adverse events being mild or moderate.
Based on these results, Amylyx plans to discuss a Phase 3 program with the FDA and provide an update in 2025. The company has been granted Orphan Drug Designation for AMX0035 in the treatment of Wolfram syndrome by the FDA and the European Commission.
The topline data from HELIOS will be presented during a live webcast today at 1:30 p.m. ET. This announcement is based on a press release statement.
In other recent news, Amylyx Pharmaceuticals announced positive results from its Phase 2 HELIOS trial evaluating AMX0035 for Wolfram syndrome treatment, demonstrating improvements in pancreatic function and other health markers among participants. The company also reported its Q2 2024 financial results, revealing a net loss of $72.7 million and a substantial cash position of $309.8 million, expected to sustain operations until 2026. Amylyx has also made significant strides in its portfolio with the acquisition of Avexitide, a treatment for hyperinsulinemic hypoglycemia that has received FDA breakthrough therapy designation. The company plans to initiate Phase 3 development for Avexitide in the upcoming year.
Furthermore, Amylyx provided updates on other key programs, including treatments for Alzheimer's disease, axonal degeneration, and various other conditions. The company maintains a focus on current assets while remaining open to potential pipeline additions. These recent developments offer a glimpse into the ongoing efforts and progress at Amylyx Pharmaceuticals.
During their Q2 2024 earnings call, the company's leaders discussed these financial results and updates on their clinical programs. The company's strong cash position and the acquisition of Avexitide were highlighted, along with the anticipated start of Phase 3 development for Avexitide in the coming year. These are the recent highlights from Amylyx Pharmaceuticals.
InvestingPro Insights
Amylyx Pharmaceuticals' positive trial results for AMX0035 in Wolfram syndrome come at a crucial time for the company. According to InvestingPro data, Amylyx has shown impressive revenue growth of 55.71% over the last twelve months as of Q2 2023, reaching $298.76 million. This growth trajectory aligns well with the company's ongoing development of promising treatments like AMX0035.
However, it's important to note that Amylyx is currently operating at a loss, with an adjusted operating income of -$177.76 million for the same period. This is not uncommon for biopharmaceutical companies investing heavily in research and development, especially those focusing on rare diseases like Wolfram syndrome.
An InvestingPro Tip suggests that Amylyx's stock price has significantly underperformed the market over the past year, with a one-year price total return of -77.19%. This could indicate that the market has not yet fully priced in the potential of AMX0035 and other pipeline products. Another InvestingPro Tip notes that analysts have revised their earnings expectations upward, which may reflect growing confidence in the company's prospects following positive trial results like those from the HELIOS study.
For investors interested in a deeper analysis, InvestingPro offers 12 additional tips for Amylyx Pharmaceuticals, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.